Filtered By:
Condition: Rheumatoid Arthritis
Drug: Hydroxychloroquine

This page shows you your search results in order of date.

Order by Relevance | Date

Total 3 results found since Jan 2013.

Cardiovascular comorbidities in rheumatoid arthritis.
Abstract Approximately 80% of patients with rheumatoid arthritis (RA) suffer from comorbidities including more than 50% from cardiovascular (CV) diseases. Inflammatory activity is the main factor connecting RA with atherosclerosis, coronary heart disease, stroke, thromboembolic events and heart failure. Altogether these affect RA patients twice as frequently as the general population and CV events are the major cause of death in RA. Besides inflammatory activity, which can be reduced or eliminated by optimal treatment and controlling the RA activity, traditional CV risk factors also contribute to the total CV ris...
Source: Zeitschrift fur Rheumatologie - January 17, 2019 Category: Rheumatology Authors: Krüger K, Nüßlein H Tags: Z Rheumatol Source Type: research

Methotrexate might reduce ischemic stroke in patients with rheumatoid arthritis: a population ‐based retrospective cohort study
ConclusionsAt a dosage of > 0.5 defined daily dose, short‐term methotrexate might decrease ischemic stroke risk in RA patients, while hydroxychloroquine and sulfasalazine were neutral.
Source: APLAR Journal of Rheumatology - January 1, 2018 Category: Rheumatology Authors: Hong ‐Wei Tam, Chyong‐Mei Chen, Pui‐Ying Leong, Chao‐Hsi Chen, Yuan‐Chao Li, Yu‐Hsun Wang, Li‐Chi Lin, Jeng‐Yuan Chiou, James Cheng‐Chung Wei Tags: Original Article Source Type: research

Hydroxychloroquine Use Is Associated With Decreased Incident Cardiovascular Events in Rheumatoid Arthritis Patients Preventive Cardiology
Conclusion In this hypothesis-generating study, hydroxychloroquine use was associated with a 72% decrease in the risk of incident CVD in RA patients. If these preliminary results are confirmed in larger studies, our findings may be used as a rationale for a randomized study of hydroxychloroquine use for primary prevention of CVD in RA or nonrheumatic high-risk patients.
Source: JAHA:Journal of the American Heart Association - January 4, 2016 Category: Cardiology Authors: Sharma, T. S., Wasko, M. C. M., Tang, X., Vedamurthy, D., Yan, X., Cote, J., Bili, A. Tags: Cardiovascular Disease, Primary Prevention Preventive Cardiology Source Type: research